People · Operator
Named in public records as an officer, director or promoter · active 2008–2022 · Pharmaceuticals, Other Technology, Other, Hospitals and Physicians, Other Health Care, Agtech / Foodtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talphera, Inc. | — | Pharmaceuticals | Series B | $97.4M | $74.2M | 2010 |
| FloSports, Inc. | — | Other Technology | Series C | $76.4M | $1.5B | 2014 |
| Access Closure, Inc. | — | Other | Series A | $23.6M | $15.6M | 2008 |
| CareConnectMD, Inc. | — | Hospitals and Physicians | Series A | $17.8M | $99.8M | 2018 |
| Squareone, Inc. | — | Other Health Care | Series A | $15.9M | $81.5M | 2009 |
| Ingenuity Systems Inc | — | Other Technology | Series B | $15.4M | $469.0M | 2010 |
| Trireme Medical Inc | — | Other Health Care | Series A | $14.7M | $153.4M | 2009 |
| Street League, Inc. | — | Other | Series A | $6.6M | $69.6M | 2014 |
| Project One Nutrition Inc. | — | Agtech / Foodtech | Series A | $5.7M | $50.0M | 2016 |
| QuintEvents, LLC | — | Other | Series A | $5.5M | $83.2M | 2017 |
Mark Wan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Wan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FARHAD KHOSRAVI | 2 | 14 |
| Amar Sawhney | 2 | 6 |
| Rob Kuhling | 2 | 3 |
| David Martin | 1 | 13 |
| Jason Krikorian | 1 | 12 |
| Jeani Delagardelle | 1 | 8 |
| Stephen Hoffman | 1 | 7 |
| Rob Dyrdek | 1 | 6 |
| Amir Belson | 1 | 6 |
| Jeffrey Lightcap | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Hank Plain | 1 | 5 |
| Guy Nohra | 1 | 5 |
| Howard B. Rosen | 1 | 4 |
| Greg Casciaro | 1 | 4 |
| Mark Edwards | 1 | 4 |
| John D. Diekman | 1 | 4 |
| James Welch | 1 | 4 |
| Richard King | 1 | 3 |
| Suresh Pai | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.